AuthorsRanson, Malcolm R
AffiliationDepartment of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractActivation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.
CitationEpidermal growth factor receptor tyrosine kinase inhibitors. 2004, 90 (12):2250-5 Br. J. Cancer
JournalBritish Journal of Cancer
- EGFR-directed therapies to treat non-small-cell lung cancer.
- Authors: Ho C, Laskin J
- Issue date: 2009 Aug
- Targeting the epidermal growth factor receptor.
- Authors: El-Rayes BF, LoRusso PM
- Issue date: 2004 Aug 2
- Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
- Authors: Baselga J, Arteaga CL
- Issue date: 2005 Apr 10
- EGFR inhibition in NSCLC: the emerging role of cetuximab.
- Authors: Herbst RS
- Issue date: 2004 Sep
- Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
- Authors: Bar J, Onn A
- Issue date: 2012 Jul